bluuebunny/crossref_metadata_2025_split huggingface dataset:
Preoperative Education for Less Outpatient Pain after Surgery (PELOPS trial) in orthopedic patients—study protocol for a randomized controlled trial
Authors: Dziadzko Mikhail , Bouteleux Axelle , Minjard Raphael , Harich Jack , Joubert Fanny , Pradat Pierre , Pantel Solene , Aubrun Frederic 
Published: May 2022

Abstract
Background
Successful pain management after outpatient surgery requires proper education leading to correct decisions on the analgesics use at home. Despite different strategies adopted, up to ½ of patients receive little or no information about the treatment of postoperative pain, 1/3 of them are not able to follow postoperative analgesia instructions. This leads to higher rates of unmet needs in pain treatment, post-discharge emergency calls, and readmissions. Structured educational interventions using psychological empowering techniques may improve postoperative pain management. We hypothesize that preoperative education on use of an improved pain scale to make correct pain management decisions will improve the quality of post-operative pain management at home and reduce analgesics-related side effects.

Methods
A total of 414 patients scheduled for an outpatient orthopedic surgery (knee/shoulder arthroscopic interventions) are included in this randomized (1:1) controlled trial. Patients in the control arm receive standard information on post-discharge pain management. Patients in the experimental arm receive structured educational intervention based on the rational perception of postoperative pain and discomfort (anchoring and improved pain scale), and the proper use of analgesics. There is no difference in post-discharge analgesics regimen in both arms. Patients are followed for 30 days post-discharge, with the primary outcome expressed as total pain relief score at 5 days. Secondary outcomes include the incidence of severe pain during 30 days, changes in sleep quality (Pittsburg Sleep Quality Assessment), and patients’ perception of postoperative pain management assessed with the International Pain Outcomes questionnaire at day 30 post-discharge.

Discussion
The developed intervention, based on an improved pain scale, offers the advantages of being non-surgery-specific, is easily administered in a short amount of time, and can be delivered individually or in-group, by physicians or nurses.

Trial registration
ClinicalTrials.govNCT03754699. Registered on November 27, 2018.
Effects of different doses of methylprednisolone on clinical outcomes in patients with severe community-acquired pneumonia: a study protocol for a randomized controlled trial
Authors: Hong Shukun , Wang Hongye , Liu Jian , Qiao Lujun 
Published: May 2022

Abstract
Background
The specific use of methylprednisolone in severe community-acquired pneumonia (SCAP) has not yet formed a consensus. It is not clear whether the clinical efficacy of methylprednisolone in SCAP is dose-dependent, and how to balance the best efficacy with the least complications. The aim of this study is to evaluate the efficacy and safety of different doses of methylprednisolone in the adjuvant treatment for patients with SCAP.

Methods/design
This is a prospective, randomized, double-blind, parallel group, placebo-controlled trial to evaluate the efficacy and safety of different doses of methylprednisolone in the adjuvant treatment for patients with SCAP. Patients with diagnosed SCAP are randomized to the following four groups at a 1:1:1:1 ratio: group 1 (control group)—standard ICU patient care+100ml of normal saline once a day for 5 days; group 2—standard ICU patient care+40mg of methylprednisolone (dissolved in normal saline with a final volume of 100ml) once a day for 5 days; group 3—standard ICU patient care+80mg of methylprednisolone (dissolved in normal saline with a final volume of 100ml) once a day for 5 days; and group 4—standard ICU patient care+120mg of methylprednisolone (dissolved in normal saline with a final volume of 100ml) once a day for 5 days. The primary outcome is PaO2/FiO2 ratio at day 5 following randomization. The secondary outcomes are 28-day mortality, ventilator-free days at 28 days, mechanical ventilation duration at 28 days, endotracheal intubation rate, time for temperature recovery, duration of vasopressors use, serum CRP and interleukin-6 level at day 5 following randomization, hospital stay, frequency of nosocomial infections, gastrointestinal hemorrhage, and hyperglycemia.

Discussion
The results of our study may find the optimal dose of glucocorticoid in the adjuvant treatment of SCAP and provide evidence-based proof for clinicians to treat patients with SCAP. Since coronavirus disease 2019 (COVID-19) also belongs to community-acquired pneumonia, perhaps the results of our study will help to determine the appropriate dose of methylprednisolone in COVID-19 treatment.

Trial registration
Chinese Clinical Trial Registry ChiCTR2100045056. Registered on 4 April 2021.
Molecular epidemiological study on ticks and tick-borne protozoan parasites (Apicomplexa: Cytauxzoon and Hepatozoon spp.) from wild cats (Felis silvestris), Mustelidae and red squirrels (Sciurus vulgaris) in central Europe, Hungary
Authors: Hornok Sándor , Boldogh Sándor A. , Takács Nóra , Kontschán Jenő , Szekeres Sándor , Sós Endre , Sándor Attila D. , Wang Yuanzhi , Tuska-Szalay Barbara 
Published: May 2022

Abstract
Background
Among live wild mammals adapted to urban and peri-urban habitats in Europe, members of the families Felidae, Mustelidae and Sciuridae deserve special attention as pathogen reservoirs because all of these families include members that are kept as pets. We report here the results of our study on two important groups of tick-borne protozoan parasites in ticks and tissues of wild cats, mustelids and red squirrels.

Methods
DNA was extracted from the tissues of carnivores (wild cats, mustelids; n = 16) and red squirrels (n = 4), as well as from ixodid ticks (n = 89) collected from these hosts. These DNA extracts were screened for piroplasms and Hepatozoon spp. using conventional PCR analysis and sequencing. In addition, 53 pooled samples of 259 questing Haemaphysalis concinna ticks were evaluated for the presence of Hepatozoon DNA, followed by phylogenetic analyses.

Results
One wild cat was found to be coinfected with Cytauxzoon europaeus and a new genotype of Hepatozoon felis, and two additional wild cats were infected with H. felis from a different phylogenetic group. In mustelids, Hepatozoon martis and two further Hepatozoon genotypes were detected. The latter clustered separately, close to others reported from eastern Asia. In addition, Hepatozoon sciuri was detected in red squirrels. Morphologic and molecular analyses verified eight tick species. One wild cat was infected with a H. felis genotype that was significantly different from that in Ixodes ricinus females infesting this cat. Only three pools of questing H. concinna nymphs tested positive for Hepatozoon, one of which contained H. martis.

Conclusions
This study provides the first evidence of the occurrence of any Cytauxzoon species and of three Hepatozoon species in Hungary. In addition to H. martis, two further mustelid-associated Hepatozoon genotypes were detected, one of which was new in terms of phylogenetic and broader geographical contexts. This may be the first indication that H. felis genotypes from both of its phylogenetic groups occur in Europe. This also appears to be the first evidence of H. felis and C. europaeus coinfection in felids in Europe, and of autochthonous H. felis infection in wild cats north of the Mediterranean Basin. New tick–host associations were also observed in this study. Based on the results, H. felis and H. martis might survive transstadially in I. ricinus and H. concinna, respectively.

Graphical Abstract
Monitoring of patients with rheumatoid arthritis by indocyanine green (ICG)-enhanced fluorescence optical imaging treated with anti-TNFα therapy
Authors: Hertrampf S. , Klotsche J. , Schefer Q. , Glimm A. M. , Burmester G. R. , Hoff P. , Schmittat G. , Häupl T. , Hermann S. , Backhaus M. , Ohrndorf Sarah 
Published: May 2022

Abstract
Background
Fluorescence optical imaging (FOI) enables visualisation of inflammation in both hands in rheumatoid arthritis (RA).

Objective
To investigate the usefulness of FOI in treatment monitoring under anti-TNFα therapy with certolizumab pegol (CZP) in patients with RA in comparison to clinical and laboratory outcome parameters.

Methods
CZP-naïve patients with RA were eligible for this open-label study with an observational period of 52 weeks. Disease activity was monitored by the clinical score DAS28, tender/swollen joint count (TJC-28/SJC-28) and laboratory outcomes for systemic inflammation (CRP and ESR). FOI results were analysed in three different phases (P1-3) and PrimaVistaMode (PVM) by the FOI activity score (FOIAS).

Results
Twenty-eight RA patients (median age 52.5 years, 26 females, thirteen with a history of other biologic therapy) were included. DAS28 (CRP) decreased from moderate disease activity at baseline (median 4.6, IQR 1.8) to low disease activity at week (w)52 (median 2.7, IQR 2.1; p < 0.001). Statistically significant decreases could also be demonstrated for SJC-28 and TJC-28. CRP/ESR were reduced numerically from baseline to w52. FOIAS in P1 (early phase) showed a continuous decrease of enhancement during the course of treatment period: from baseline (median 1.5, IQR 9.3) over w6 (median 1.0, IQR 3.0; p = 0.069), w12 (median 0.5, IQR 3.0; p = 0.171), w24 (n = 27, median 0.0, IQR 3.0; p = 0.004), until w52 (n = 18, median 0.0, IQR 2.8; p = 0.091), which could not be presented for FOIAS in P2, P3 and PVM.

Conclusion
FOI in P1 appears to be a valuable tool for fast and easy monitoring of treatment response to certolizumab in a clinical setting.
Judo specific fitness test performance variation from morning to evening: specific warm-ups impacts performance and its diurnal amplitude in female judokas
Authors: Eken Özgür , Clemente Filipe Manuel , Nobari Hadi 
Published: May 2022

Abstract
Background
A number of specific tests are used to standardize competition performance. Specific Judo fitness test (SJFT) can be applied by considering the start of the competition qualifiers in the morning and the continuation of the final competitions in the evening. The improvement of test performances can be achieved with warm-up for elevating heart rate (HR) and muscle temperature such as raise, activate, mobilise, potentiate (RAMP) protocols.

Purpose
The aim of this study is to evaluate the effects of different warm-up protocols on SJFT at different times of the day in female judokas.

Methods
Ten volunteer women participated in this study, who regularly participated in judo training for more than 5 years and actively competed in international competitions. Judokas completed SJFT, either after no warm-up, or RAMP protocols like specific warm-up (SWU), and dynamic warm-up for two times a day in the morning: 09:00–10:00 and in the evening: 16:00–17:00, with at least 2 days between test sessions. The following variables were recorded: throws performed during series A, B, and C; the total number of throws; HR immediately and 1 min after the test, and test index after different warm-ups.

Results
When analyzed evening compared to the morning without discriminating three warm-up protocols, evening results statistically significant number of total throws performed during series A, B, and C, the total number of throws; HR immediately and 1 min after the test, and test index than morning results (p < 0.01). Moreover, RAMP protocols interaction with time have demonstrated an impact on SJFT for index [F(2) = 4.15, p = 0.024, ηp2: 0.19] and changes after 1 min HR [F(1.370)= 7.16, p = 0.008, ηp2: 0.29]. HR after 1 min and test index results were statistically significant in favor of SWU (p < 0.05).

Conclusions
In conclusion, SJFT performance showed diurnal variation and judo performances of the judokas can be affected more positively in the evening hours especially after RAMP protocols.
ADataViewer: exploring semantically harmonized Alzheimer’s disease cohort datasets
Authors: Salimi Yasamin , Domingo-Fernández Daniel , Bobis-Álvarez Carlos , Hofmann-Apitius Martin , Birkenbihl Colin ,   for the Alzheimer’s Disease Neuroimaging Initiative, the Japanese Alzheimer’s Disease Neuroimaging Initiative, for the Aging Brain: Vasculature, Ischemia, and Behavior Study, the Alzheimer’s Disease Repository Without Borders Investigators, for the European Prevention of Alzheimer’s Disease (EPAD) Consortium
Published: May 2022

AbstractBackgroundCurrently, Alzheimer’s disease (AD) cohort datasets are difficult to find and lack across-cohort interoperability, and the actual content of publicly available datasets often only becomes clear to third-party researchers once data access has been granted. These aspects severely hinder the advancement of AD research through emerging data-driven approaches such as machine learning and artificial intelligence and bias current data-driven findings towards the few commonly used, well-explored AD cohorts. To achieve robust and generalizable results, validation across multiple datasets is crucial.MethodsWe accessed and systematically investigated the content of 20 major AD cohort datasets at the data level. Both, a medical professional and a data specialist, manually curated and semantically harmonized the acquired datasets. Finally, we developed a platform that displays vital information about the available datasets.ResultsHere, we present ADataViewer, an interactive platform that facilitates the exploration of 20 cohort datasets with respect to longitudinal follow-up, demographics, ethnoracial diversity, measured modalities, and statistical properties of individual variables. It allows researchers to quickly identify AD cohorts that meet user-specified requirements for discovery and validation studies regarding available variables, sample sizes, and longitudinal follow-up. Additionally, we publish the underlying variable mapping catalog that harmonizes 1196 unique variables across the 20 cohorts and paves the way for interoperable AD datasets.ConclusionsIn conclusion, ADataViewer facilitates fast, robust data-driven research by transparently displaying cohort dataset content and supporting researchers in selecting datasets that are suited for their envisioned study. The platform is available athttps://adata.scai.fraunhofer.de/.
Regeneration difficulties in patients with FQAD can limit the use of iPSc-based cell therapy
Authors: Grot Dagmara , Wasiak Katarzyna , Tyszkowski Jerzy , Stoczynska-Fidelus Ewelina , Ochedalski Tomasz P. , Rieske Piotr 
Published: May 2022

AbstractEtiopathogenesis of fluoroquinolone-associated disability (FQAD) syndrome is not fully understood, yet research could progress by utilizing induced pluripotent stem cells (iPSc) from people with this syndrome. Similarly, iPSc, or rather their derivatives, could be used in their therapy, not only for FQAD but also for other disorders in which generated autologous iPSc and their derivatives might be helpful. Urine was collected from ten donors with FQAD, and reprogramming of these cells was conducted with the use of Epi5TM Episomal iPSC Reprogramming Kit. IPSc were generated in one out of ten person’s urine cells. While urinary cells are considered the easiest mature cells to be reprogrammed into iPSc, the urinary cells from six consecutive donors quickly became senescent. Stable urine primary cell cultures could not be obtained from the three remaining donors. Repeated attempts to reprogram epithelial cells were not successful. During parallel studies conducted for healthy donors, reprogramming success was achieved in six out of ten cases. These data may suggest serious limitations in the regeneration system of individuals with FQAD. Consequently, it indicates that therapy with autologous iPSc derivatives may face serious difficulties in their case, still, the first iPSc cell line from a person with FQAD was established.
Improving sign-algorithm convergence rate using natural gradient for lossless audio compression
Authors: Mineo Taiyo , Shouno Hayaru 
Published: May 2022

AbstractIn lossless audio compression, the predictive residuals must remain sparse when entropy coding is applied. The sign algorithm (SA) is a conventional method for minimizing the magnitudes of residuals; however, this approach yields poor convergence performance compared with the least mean square algorithm. To overcome this convergence performance degradation, we propose novel adaptive algorithms based on a natural gradient: the natural-gradient sign algorithm (NGSA) and normalized NGSA. We also propose an efficient natural-gradient update method based on the AR(p) model, which requires $\mathcal {O}(p)$
O
(
p
)
multiply–add operations at every adaptation step. In experiments conducted using toy and real music data, the proposed algorithms achieve superior convergence performance to the SA. Furthermore, we propose a novel lossless audio codec based on the NGSA, called the natural-gradient autoregressive unlossy audio compressor (NARU), which is open-source and implemented in C. In a comparative experiment with existing, well-known codecs, NARU exhibits superior compression performance. These results suggest that the proposed methods are appropriate for practical applications.
Cognitive Remediation and Social Recovery in Early Psychosis (CReSt-R): protocol for a pilot randomised controlled study
Authors: Frawley E. , Cowman M. , Cella M. , Cohen D. , Ryan E. , Hallahan B. , Bowie C. , McDonald C. , Fowler D. , Wykes T. , Donohoe G. 
Published: May 2022

AbstractBackgroundPsychosis, even in its early stages, is associated with significant disability, causing it to be ranked ahead of paraplegia and blindness in those aged 18–35 in terms of years lived with disability. Current pharmacological and psychological interventions intervention have focused primarily on the reduction of positive symptoms (hallucinations and delusions), with little benefit to domains of psychosis such as cognitive difficulties and social and occupational functioning.Methods/designThe CReSt-R intervention trial is a single center, pilot randomised controlled study based at the National University of Ireland (NUI), Galway. The trial will recruit participants from four clinical sites with assessment and intervention completed by the primary NUI Galway team. The trial will explore the feasibility, acceptability, and effectiveness of a novel psychosocial intervention for early psychosis based on a combined cognitive remediation training and cognitive behavioural therapy approach focused on social recovery. Participants, aged 16–35 within the first 5 years of a diagnosed psychotic disorder, will be recruited from the Children and Adolescent Mental Health Service and the Adult Mental Health Services in the region.DiscussionCognitive remediation training (for improving cognition) and social recovery focused cognitive behavioural therapy, have both separately demonstrated effectiveness. This trial will evaluate the feasibility, acceptability, and explore the efficacy of a treatment approach that combines both approaches as part of an integrated, multicomponent intervention.Trial registrationCognitive Remediation & Social Recovery in Early Psychosis (CReSt-R):ClincialTrials.govIdentifier NCT04273685. Trial registered Feb 18th, 2020. Last updated April 14th, 2021.
Divergent Roles of α5 and β4 Nicotinic Receptor Subunits in Food Reward and Nicotine-induced Weight Loss in Male Mice
Authors: Breum Alberte Wollesen , Falk Sarah , Svendsen Charlotte Sashi Aier , Nicolaisen Trine Sand , Mathiesen Cecilie Vad , Maskos Uwe , Clemmensen Christoffer 
Published: May 2022

Abstract
A major obstacle to successful smoking cessation is the prospect of weight gain. Despite a clear relationship between cigarette smoking and body weight, surprisingly little is known about the physiological and molecular mechanism by which nicotine affects energy homeostasis and food-motivated behaviors. Here we use loss-of-function mouse models to demonstrate that 2 nicotinic acetylcholine receptor (nAChR) subunits encoded by the CHRNA5-CHRNA3-CHRNB4 gene cluster, α5 and β4, exhibit divergent roles in food reward. We also reveal that β4-containing nAChRs are essential for the weight-lowering effects of nicotine in diet-induced obese mice. Finally, our data support the notion of crosstalk between incretin biology and nAChR signaling, as we demonstrate that the glycemic benefits of glucagon-like peptide-1 receptor activation partially relies on β4-containing nAChRs. Together, these data encourage further research into the role of cholinergic neurotransmission in regulating food reward and the translational pursuit of site-directed targeting of β4-containing nAChRs for treatment of metabolic disease.
Hippo Signaling in the Ovary: Emerging Roles in Development, Fertility, and Disease
Authors: Clark Kendra L , George Jitu W , Przygrodzka Emilia , Plewes Michele R , Hua Guohua , Wang Cheng , Davis John S 
Published: May 2022

Abstract
Emerging studies indicate that the Hippo pathway, a highly conserved pathway that regulates organ size control, plays an important role in governing ovarian physiology, fertility, and pathology. Specific to the ovary, the spatiotemporal expression of the major components of the Hippo signaling cascade are observed throughout the reproductive lifespan. Observations from multiple species begin to elucidate the functional diversity and molecular mechanisms of Hippo signaling in the ovary in addition to the identification of interactions with other signaling pathways and responses to various external stimuli. Hippo pathway components play important roles in follicle growth and activation, as well as steroidogenesis, by regulating several key biological processes through mechanisms of cell proliferation, migration, differentiation, and cell fate determination. Given the importance of these processes, dysregulation of the Hippo pathway contributes to loss of follicular homeostasis and reproductive disorders such as polycystic ovary syndrome (PCOS), premature ovarian insufficiency, and ovarian cancers. This review highlights what is currently known about the Hippo pathway core components in ovarian physiology, including ovarian development, follicle development, and oocyte maturation, while identifying areas for future research to better understand Hippo signaling as a multifunctional pathway in reproductive health and biology.
Is schizophrenia just a mental illness? - The correlation between schizophrenia and cancer
Authors: Wróblewski Hubert , Chojęta Dariusz , Zimna Aleksandra , Zygmunt Ewelina , Wróblewska Kinga 
Published: May 2022

Introduction and purpose of the work:Schizophrenia is a mental illness that affects approximately 24 million people worldwide. It is characterized by hallucinations, most often auditory, delusions, blunted affect, and distortions of thought, such as echoes of thought and perception. There is a predisposition to more frequent diabetes, metabolic syndrome, hormonal disorders, cardiovascular diseases and respiratory diseases, even in patients not treated with antipsychotics. In connection with the above, the question may arise whether schizophrenia also predisposes to developing other diseases, such as cancer. The aim of this article is to present the relationship between the occurrence of schizophrenia and cancer.
State of knowledge:There was no correlation between an increased incidence of lung cancer and schizophrenia, however, the analyzed studies were not homogeneous. In the case of breast cancer, data suggest a higher incidence of breast cancer among people with psychiatric disorders. In prostate cancer, a lower risk of developing the disease has been reported in patients with schizophrenia. It should be noted that despite the predisposition of people with schizophrenia to addiction to stimulants, low physical activity, the increase in the risk of cancer in some studies was not very high.
Summary: It can be noticed that there is a correlation between the occurrence of schizophrenia and the predisposition to developing malignant neoplasms. Currently, hope is placed on their use in anti-cancer therapy.